Eupraxia Pharmaceuticals Inc.
TSX:EPRX.TOBiotechnology
Healthcare
$8.86 +2.49%
+$0.22 today
- Market cap
- $595.76M
- Beta
- 1.48
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.74
52W Low $5.82High $12.86
Volume 0.16M
Average 0.05M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$39.11M
FY 2025 · Annual
Net Income
-$39.25M
FY 2025 · Annual
Income Statement
Mixed currencies
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · USD | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 111.53K | 193.27K | 158.05K | 163.47K | 241.88K |
| Gross Profit | (111.53K) | (193.27K) | (158.05K) | (163.47K) | (241.88K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 10.17M | 17.58M | 21M | 15.17M | 21.51M |
| Selling, General & Admin | 8.2M | 5.81M | 7.37M | 10.92M | 17.1M |
| Operating Expenses | 18.38M | 23.38M | 28.37M | 25.54M | 38.86M |
| Depreciation & Amortization | 111.53K | 193.27K | 158.05K | 163.47K | 241.88K |
| EBITDA | (21.96M) | (22.14M) | (28.16M) | (23.43M) | (38.86M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (18.47M) | (23.58M) | (27.78M) | (25.71M) | (39.11M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 65.73K | 569.32K | 876.96K | 1.1M | 1.44M |
| Interest Expense | 1.3M | 1.59M | 1.19M | 913.1K | 0 |
| Other Income / Expenses | (4.9M) | (341.09K) | (1.08M) | 1.2M | (155.19K) |
| Income Before Tax | (23.37M) | (23.92M) | (28.93M) | (24.51M) | (39.26M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | (67.51K) | 1.72K | 19.42K |
| Net Income | (22.99M) | (23.26M) | (28.15M) | (24.28M) | (39.25M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.61) | (1.21) | (1.19) | (0.72) | (1.05) |
| EPS (Diluted) | (1.61) | (1.21) | (1.19) | (0.72) | (1.05) |
| 14.24M | 19.29M | 24.15M | 33.93M | 39.96M | |
| 14.24M | 19.29M | 24.15M | 33.93M | 39.96M |
EPRX.TO Earnings Waterfall · TTM
TSX:EPRX.TO · Revenue to Net Income
Key Ratios
EPS$-1.02
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-10.3
P/S Ratio0.0
Analysis
$0 of revenue converted into -$42.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.02, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
No filings found.
How much revenue does EPRX.TO generate?
Eupraxia Pharmaceuticals Inc. (EPRX.TO) reported $0.00 of revenue in fiscal 2025.
Is EPRX.TO profitable?
Eupraxia Pharmaceuticals Inc. (EPRX.TO) reported -$39.25M of net income.
Continue the stock analysis
Jump to another research area for this company.